Details for Patent: 9,452,194

Title:	Methods for treating HCV
Abstract:	The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
Inventor(s):	Awni; Walid M. (Green Oaks, IL), Bernstein; Barry M. (Mequon, WI), Brun; Scott C. (Green Oaks, IL), Cohen; Daniel E. (Wilmette, IL), Dumas; Emily O. (Libertyville, IL), Dutta; Sandeep (Lincolnshire, IL), Khatri; Amit (Glenview, IL), Klein; Cheri E. (Northbrook, IL), Menon; Rajeev M. (Buffalo Grove, IL), Mensing; Sven (Mannheim, DE), Podsadecki; Thomas J. (Northbroook, IL)
Assignee:	AbbVie Inc. (North Chicago, IL)
Filing Date:	Oct 01, 2014
Application Number:	14/503,849
Claims:	1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) and ribavirin to a patient infected with HCV genotype 1, wherein said treatment lasts for 24 weeks and does not include administration of interferon to said patient, wherein said at least two DAAs comprise Compound 1 ##STR00012## and Compound 4 ##STR00013## and wherein Compound 1 is administered with ritonavir. 2. The method of claim 1, wherein said patient is a treatment-naive patient. 3. The method of claim 1, wherein said patient is an interferon null responder. 4. The method of claim 1, wherein said Compound 1, ritonavir and Compound 4 are co-formulated in a single composition and administered once daily. 5. The method of claim 1, wherein said Compound 1 is administered 150 mg once daily together with 100 mg ritonavir once daily, and said Compound 4 is administered 25 mg once daily. 6. The method of claim 1, wherein said Compound 1, ritonavir and Compound 4 are co-formulated in a single composition. 7. The method of claim 1, wherein said at least two DAAs further comprise Compound 2 ##STR00014## 8. The method of claim 7, wherein said patient is a treatment-naive patient. 9. The method of claim 7, wherein said patient is an interferon null responder.